ARK Genomic Revolution ETF (ARKG)

BATS: ARKG · IEX Real-Time Price · USD
34.62
+0.96 (2.85%)
Jun 24, 2022 4:00 PM EDT - Market closed
2.85%
Assets $2.58B
NAV $33.66
Expense Ratio 0.75%
PE Ratio n/a
Shares Out 76.70M
Dividend (ttm) $0.38
Dividend Yield 1.10%
Ex-Dividend Date Dec 29, 2021
1-Year Return -62.69%
Volume 641,846
Open 44.12
Previous Close 33.66
Day's Range 33.01 - 34.64
52-Week Low 37.94
52-Week High 94.14
Beta 1.53
Holdings 49
Inception Date Oct 31, 2014

About ARKG

The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.

Asset Class Portfolio-Multi Asset
Sector Biotech
Region Global
Issuer Ark Funds
Stock Exchange BATS
Ticker Symbol ARKG

Top 10 Holdings

47.31% of assets
Name Symbol Weight
Exact Sciences EXAS 7.12%
Ionis Pharmaceuticals IONS 6.56%
Teladoc Health TDOC 5.19%
CRISPR Therapeutics AG CRSP 4.84%
Signify Health SGFY 4.59%
Fate Therapeutics FATE 4.26%
CareDx CDNA 3.87%
Twist Bioscience TWST 3.75%
Vertex Pharmaceuticals VRTX 3.60%
Incyte INCY 3.53%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 29, 2021 $0.38239 Dec 31, 2021
Dec 29, 2020 $0.79013 Dec 31, 2020
Dec 27, 2019 $1.05395 Dec 31, 2019
Dec 27, 2018 $0.46634 Dec 31, 2018
Dec 27, 2017 $0.32769000000000004 Dec 29, 2017
Full Dividend History

News

Get Exposure to the Genomic Revolution With ARKG

Ultima Genomics has claimed that its first instrument, the UG100, will sequence a human genome for under $100. The news surprised and perhaps delighted the life sciences community, as the price to seque...

An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome

With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, an...

Change the DNA of Your Portfolio: Growth Opportunities Through Genomics

Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech compa...

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Other symbols: BNREDITIONS

Some ARKG Components Could Lead in Genetic Testing

In the healthcare space, it's often said that an ounce of prevention is worth a pound of cure, and that's undeniably true when it comes to cancer prevention and treatment. A clear avenue for bolstering ...

Ark is Sinking: Can Cathie Wood Bounce Back?

Catherine Wood (Trades, Portfolio) is a growth stock investor who believes disruptive innovation and technology are the keys to great investing returns. Her firm's flagship fund, the Ark Innovation ETF ...

Other symbols: ARKFARKKARKQ

ARK Crushed By Concentrated Bet In Teladoc

Shares of the telemedicine provider were cut in half on Thursday, pressuring ARKK and other ETFs.

Other symbols: TDOCARKFARKKARKW

Why Investors Should Consider ETFs That Target Innovation Platforms

Investors should keep an eye on innovative platforms-related exchange traded funds to capture tomorrow's growth ideas today. In the recent webcast, Refining Your Innovation Exposure: How to Access Tomor...

Other symbols: ARKKARKQARKWARKX

Refining Your Innovation Exposure: How to Access Tomorrow's Opportunities

ARK's research identifies five innovation platforms that are evolving simultaneously, transforming the world around us. These platforms are Artificial Intelligence (AI), Blockchain Technology, Energy St...

Other symbols: ARKKARKQARKW

Cathie Wood Snaps Back At Critics, Predicts 50% Annual Returns

The ARK CEO remains steadfast in her belief that her exchange-traded funds will outperform again.

Other symbols: ARKKARKWSARK

In Genomics, Tech Matters

Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today. That's a strong indication that disruptive technologies often intersect with and dep...

Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine

Disruptive technology-related exchange traded funds rallied on Tuesday as U.S. markets turned risk-on, following positive updates on Russia and Ukraine's negotiations. Among the best-performing non-leve...

Other symbols: ARKFARKKARKW

Invest in Next-Gen Technologies With These 2 ETFs

These funds focus on revolutions in healthcare and technology.

Other symbols: BOTZ

Teladoc Endorsement Could Be Positive for This ETF

Healthcare innovation equities are languishing, but it could time for one of the most well-known names in the group to turn around, and that could be constructive for select exchange traded funds, inclu...

Ark is Sinking - Will Ark Invest Recover?

Catherine Wood (Trades, Portfolio) (Trades, Portfolio) is a growth stock investor who believes innovation and technology are the keys to great investing returns. Her flagship fund, the Ark Innovation ET...

Other symbols: ARKFARKKARKW

Volatility Is Not a Bad Word With a Long-Term Time Horizon

While disruptive innovation strategies may experience short-term volatility, ARK's research shows that maintaining a long-term investment time horizon is critical for investors searching for potential r...

Other symbols: ARKKARKQARKW

7 Megatrend Stock ETFs With Massive Potential

In 2022, the U.S. equities market got off to its worst start to a year since the dark days of the financial crisis, with many areas of the market, including stocks and stock exchange-traded funds (ETFs)...

A Bright Outlook for Gene Editing Investing

With biotechnology stocks, particularly those in mid- and small-cap territory, heavily out of favor at the moment, it's not surprising that some investors are ignoring genomics assets. That sentiment be...

Cathie Wood Explains Why Ark Investment Sends A Daily Email Disclosing Stock Moves

Every night, an email comes out from Ark Investment Management highlighting the stocks that were bought or sold by the firm's ETFs. In recent months, the emails have been known to cause certain stocks t...

Other symbols: ARKFARKKARKW

Gene Editing Stocks Might Be Building Some Momentum

Experienced healthcare and biotechnology investors know that January brings the arrival of the widely followed JPMorgan healthcare conference. This year, it's taking place in virtual fashion, but that's...

Pfizer/Beam Deal Highlights In Vivo Potential

It's just one deal, but genomics companies with exposure to in vivo gene editing may be getting a much-needed boost after blue-chip pharmaceuticals company Pfizer (NYSE:PFE) announced a related agreemen...

Other symbols: ARKK

Yield Spikes Muddy ARK's Waters

Cathie Wood's multibillion-dollar funds are off to a rocky start in 2022.

Other symbols: ARKFARKKARKQARKW

Should You Bet on Cathie Wood in 2022?

Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?

Other symbols: ARKKCTRU

How Did Cathie Wood's ARK Invest Perform in 2021?

Let's take a look at how ARK Invest ETFs performed in 2021.

Other symbols: ARKFARKKARKQARKWPRNT

CRISPR Could Come Alive in 2022

Clustered regularly interspaced short palindromic repeats, colloquially known as CRISPR, is one of the bedrocks of the genomics investment thesis, and it could be poised for big things in 2022. If that'...